Biomarker ID | 796 |
PMID | 22052531 |
Year | 2011 |
Biomarker | hsa-mir-141; hsa-mir-298; hsa-mir-375 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-375] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(miRNA-141):- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Include(miR-298):- DNA-binding transcription factor activity, RNA polymerase II-specific; nuclear chromatin; synapse;Golgi apparatus; positive regulation of gene expression Pathways Include(miRNA- 375):-DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome |
Experiment | Normal Vs Primary Tumor |
Type of Biomarker | Diagnostic |
Cohort | 128 primary prostate cancers, 29 non-malignant tissues and 14 metastases were selected for the study. GEO accession number: GSE21036 |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p≤ 0.05 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | hsa-mir-141, hsa-mir-298, hsa-mir-375 |